星空游戏网站免费进入|星空彩票电脑版

Abstract

CLC Number:

R964

ZHANG Kuo，YANG Jing-yu，WU Chun-fu.Progress on Pathophysiology and Animal Models of Depression[J]. Acta Neuropharmacologica, 2017, 7(4): 8-16.

[1] 何海然, 薛占霞. 抑郁症相关发病机制的研究进展[J]. 神经药理学报, 2016, 6(2):20-25.

[2] Ferrari F, Villa R F. The neurobiology of depression: an integrated overview from biological theories to clinical evidence[J]. Molecular Neurobiology, 2016. 54(7):1-19.

[3] 董栋, 王蕊. 抑郁症相关受体、细胞因子及信号通路的研究进展[J]. 神经药理学报, 2012, 24(5):24-30.

[4] Siegfried Kasper, Emmanuelle Corruble, Anthony Hale, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control[J]. Int Clin Psychopharmacol, 2013, 28(1):12-19.

[5] Danielle M Gerhard, Eric S Wohleb, Ronald S Duman. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity[J]. Drug Discovery Today, 2016, 21(3):454-464.

[6] Kushall Kumar, Sorabh Sharma, Puneet Kumar, et al. Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders[J]. Pharmacology Biochemistry & Behavior, 2013, 110(8):174-184.

[7] Ian Mahar, Francis Rodriguez Bambico, Naguid Mechawar, et al. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects[J]. Neuroscience & Biobehavioral Reviews, 2014, 38:173-192.

[8] Mario F Juruena. Early-life stress and HPA axis trigger recurrent adulthood depression[J]. Epilepsy & Behavior E & B, 2014, 38:148-159.

[9] Ronald S Duman. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections[J]. Depression & Anxiety, 2014, 31(4):291-6.

[10] Carmine M Pariante, Stafford L Lightman. The HPA axis in major depression: classical theories and new developments[J]. Trends in Neurosciences, 2008, 31(9): 464-468.

[11] Thomas Frodl, Veronica O'Keane. How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans[J]. Neurobiology of Disease, 2013, 52(4):24-37.

[12] Mario F Juruena, Anthony J Cleare, Andrew S Papadopoulos, et al. Different responses to dexamethasone and prednisolone in the same depressed patients[J]. Psychopharmacology, 2006, 189(2): 225-235.

[13] Chloe Farrell, Veronica O'Keane. Epigenetics and the glucocorticoid receptor: A review of the implications in depression[J]. Psychiatry Research, 2016, 242:349-356.

[14] Dirk Jan Saaltink, Erno Vreugdenhil. Stress, glucocorticoid receptors, and adult neurogenesis: a balance between excitation and inhibition?[J]. Cellular & Molecular Life Sciences Cmls, 2014, 71(13):2499-515.

[15] Christoph Anacker, Patricia A Zunszain, Livia A Carvalho, et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?[J]. Psychoneuroendocrinology, 2011, 36(3):415-25.

[16] Sabine Chourbaji, Miriam A Vogt, Peter Gass. Mice that under- or overexpress glucocorticoid receptors as models for depression or posttraumatic stress disorder[J]. Progress in Brain Research, 2008, 167:65–77.

[17] Jana Haase, Eric Brown. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression--a central role for the serotonin transporter?[J]. Pharmacol Ther, 2015, 147, 1-11

[18] Angelika Eggert, Michael A Grotzer, Naohiko Ikegaki, et al. Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma[J]. Medical & Pediatric Oncology, 2015, 35(6):569-572.

[19] Quesseveur G, David D J., Gaillard M C., et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities[J]. Translational Psychiatry, 2013, 3(4):e253.

[20] Hiroyuki Koike, Kenichi Fukumoto, Michihiko Iijima, et al. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression[J]. Behavioural Brain Research, 2013, 238(2):48-52.

[21] Glenda M MacQueen, Stephanie Campbell, Bruce S McEwen. Course of illness, hippocampal function, and hippocampal volume in major depression[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(3): 1387-1392.

[22] Robert M Sapolsky. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders[J]. Archives of General Psychiatry, 2000, 57(10): 925-935.

[23]Bruce S McEwen. Stress and hippocampal plasticity[J]. Annual Review of Neuroscience, 1999, 22: 105-122.

[24]Robert Schloesser, Dennisse Jimenez, Sophie Orvoen, et al. Antidepressant-like effects of electroconvulsive seizures require adult neurogenesis in a neuroendocrine model of depression[J]. Brain Stimulation, 2015, 8(5):862-867.

[25] Luca Santarelli, Michael Saxe, Cornelius Gross, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants[J]. Science, 2003, 301(5634): 805-809

[26]Maes M, Vandoolaeghe E, Ranjan R, et al. Increased serum interleukin-1-receptor-antagonist concentrations in major depression[J]. J Affective Disorders, 1995, 36(1): 29-36

[27] Cheryl A Kassed, Miles Herkenham. NF-κB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety[J]. Behavioural Brain Research, 2004, 154(2): 577-584.

[28] Benrick A, Schéle E, Pinnock S B, et al. Interleukin‐6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei[J]. J Neuroendocrinology, 2009, 21(7): 620-628.

[29] Roger D Porsolt, Guy Anton, Nadine Blavet. Behavioural despair in rats: a new model sensitive to antidepressant treatments [J]. Eur J Pharmacol, 1978, 47(4): 379-391.

[30] Lucien Steru, Raymond Chermat, Bernard Thierry, et al. The tail suspension test: a new method for screening antidepressants in mice [J]. Psychopharmacology, 1985, 85(3): 367-370.

[31]Seligman M E, Beagley G. Learned helplessness in the rat [J]. J. Comp. Physiol. Psychol, 1975, 88(2): 534-541.

[32]Katz R J, Roth K A, Carroll B J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression [J]. Neurosci Biobehav Rev, 1981, 5 : 247-251.

[33]Willner P, Towell A, Sampson D, et al. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant [J]. Psychopharmacology, 1987, 93(3): 358-364.

[34]Su Guang-yue, Yang Jing-yu, Wang Fang, et al. Antidepressant-like effects of Xiaochaihutang in a rat model of chronic unpredictable mild stress[J]. J Ethnopharmacology, 2014, 152(1):217-26.

[35]Harlow H F, Dodsworth R O, Harlow M K. Total social isolation in monkeys [J]. Proc Natl Acad Sci U S A, 1965, 54(1): 90-97.

[36]Greg Miller. Social neuroscience. Why loneliness is hazardous to your health[J]. Science, 2011, 331(6014), 138-140.

[37]Liesl M Heinrich, Eleonora Gullone. The clinical significance of loneliness: a literature review[J]. Clin Psychol Rev, 2006, 26(6): 695-718.

[38]Ma Jie, Wu Chun-fu, Wang Fang, et al. Neurological mechanism of Xiaochaihutang's antidepressant‐like effects to socially isolated adult rats[J]. J Pharmacy & Pharmacology, 2016, 68(10):1340-1349.

[39] Yong-ku Kim, Kyoung-Sae Na, Aye-Mu Myint, et al. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression[J]. Progress in Neuropsychopharmacology & Biological Psychiatry, 2016, 64:277-284.

[40] Pariante, C.M., Lightman, S.L. The HPA axis in major depression: classical theories and new developments [J]. Trends in neurosciences, 2008, 31 : 464-468.与10重复

[41] Charles B Nemeroff, William Gomes Vale. The neurobiology of depression: inroads to treatment and new drug discovery [J]. J Clinical Psychiatry, 2005, 66: 7, 5-13.

[42] Zhao Yun-an, Ma Ru, Shen Jia, et al. A mouse model of depression induced by repeated corticosterone injections[J]. J European Pharmacology, 2008, 581(1-2):113.

[43] Yi Li-tao, Li Jing, Li Huo-chen, et al. Ethanol extracts from Hemerocallis citrina attenuate the decreases of brain-derived neurotrophic factor, TrkB levels in rat induced by corticosterone administration [J]. J. Ethnopharmacol, 2012, 144 : 328-334.

[44] Zhang Kuo, Pan Xing, Wang Fang, et al. Baicalin promotes hippocampal neurogenesis via SGK1- and FKBP5-mediated glucocorticoid receptor phosphorylation in a neuroendocrine mouse model of anxiety/depression[J]. Scientific Reports, 2016, 6:30951.

[45] Zhang Kuo, Yang Jing-yu, Wang Fang, et al. Antidepressant-like effects of Xiaochaihutang in a neuroendocrine mouse model of anxiety/depression[J]. J Ethnopharmacology, 2016, 194:674-683.

[46] Walter Tornatzky, Klaus A Miczek. Long-term impairment of autonomic circadian rhythms after brief intermittent social stress[J]. Physiology & Behavior, 1993, 53(5):983-993.

[47] Zhang Kuo, Wang Fang, Yang Jing-yu, et al. Analysis of main constituents and mechanisms underlying antidepressant-like effects of Xiaochaihutang in mice[J]. J Ethnopharmacology, 2015, 175:48-57.

[48] Su Guang-yue, Yang Jing-yu, Wang Fang, et al. Xiaochaihutang prevents depressive-like behaviour in rodents by enhancing the serotonergic system[J]. J Pharmacy & Pharmacology, 2014, 66(6):823-34.

[49] Catherine Belzung, Paul Willner, Pierre Philippot. Depression: from psychopathology to pathophysiology[J]. Current Opinion in Neurobiology, 2015, 30:24-30.

[50] Bartlomiej Pochwat, Magdalena Sowa-Kucma, Katarzyna Kotarska, et al. Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway[J]. Psychopharmacology, 2015, 232(2):355-367.

[51] Nico Liebenberg, Samia R L Joca, Gregers Wegener. Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression[J]. Acta Neuropsychiatrica, 2015, 27(2):90-96.

[52] Laurent Naudon, Malika EI Yacoubi, Jean-Marie Vaugeois, et al. A chronic treatment with fluoxetine decreases 5-HT?A receptors labeling in mice selected as a genetic model of helplessness[J]. Brain Research, 2002, 936(1):68-75.

[53] Yousef Tizabi, Babur H Bhatti, Kebreten Manaye, et al. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto rats[J]. Neuroscience, 2012, 213(213):72-80.

[54] Dipesh Chaudhury, Jessica J Walsh, Allyson K Friedman, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons[J]. Nature, 2013, 493(7433):532-6.

[55] Kay M Tye, Julie J Mirzabekov, Melissa R Warden, et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour[J]. Nature, 2013, 493(7433):537.

Progress on Pathophysiology and Animal Models of Depression

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	LI Jia-jie, LIU Jin-xing, ZHOU Ze, WANG Ya-ping, LIAO Jia-bao, LUO Cheng, YAN He-guo, LI Hong-mei, LI Qin, WEN Wei-bo.Research on the Animal Model of Type 2 Diabetes Mellitus with Damp-Heat Syndrome in Combination with Disease Evidence: A Review[J]. ACTA NEUROPHARMACOLOGICA, 2025, 15(3): 38-.
[2]	LI Xiao-dan, CHEN Ming, ZHENG Ying, WANG Zhi-jian, HUANG Ren-chun.Effects of Sertraline Combined with CCBT on Clinical Symptoms and Self-Care Abilities in Patients with Post-Schizophrenia Depression[J]. ACTA NEUROPHARMACOLOGICA, 2025, 15(1): 19-.
[3]	ZHANG Wei-jian, ZHAO Yun-hao, JIA Chong-ning, QIN Xue-mei, TIAN Jun-sheng.Research Progress on the Treatment of Depression with Chinese Medicine by Regulating Brain Sex Hormone Microenvironment Homeostasis[J]. ACTA NEUROPHARMACOLOGICA, 2025, 15(1): 25-.
[4]	ZHOU Xin-mei, ZHU Li-ping.Network Pharmacology Study of Sini SAN in the Treatment of Post-Stroke Depression[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 19-.
[5]	ZHANG Ran-ran, WU Zhi-gang.Research Progress of Neuroactive Steroid in the Treatment of Depression[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(1): 49-.
[6]	HUANG He, LAN Yue-ying.Clinical Efficacy of Amsulpride Combined with Duloxetine in Treatment of Depression in Forced Detoxification Patients[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(5): 43-.
[7]	HUANG Yu-li, LI Xiang-bo, YUAN li, TENG Jin-liang.Research Progress on Clinical Efficacy and Adverse Reactions of Esketamine[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(4): 13-.
[8]	WANG Qian-ru, HOU Jiu-wen, MEI Qi-bing.Research Progress on Animal Models of Human Kidney Disease[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(4): 29-.
[9]	NIU Cong, WU Zhi-gang.Research Progress of Traditional Chinese Medicine in the Treatment of Depression[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(1): 49-.
[10]	CUI Pei, SUN Yu-jiao, CHEN Jing-jing, ZHANG Xin-yu, DONG Yan-hong.Research Progress on the Application of Accelerated Repetitive Transcranial Magnetic Stimulation[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(3): 23-.
[11]	ZHAO Bo, YU Ai-mei, ZOU Yu-an.Research Progress of Cortical Spreading Depression[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(3): 28-.
[12]	WEI Yuan-yuan, ZHANG Yan-nan, FAN Yi-meng, GA Yu, WANG Hui-ru, HAN Jun-cheng, LV Jian-yu, HAO Zhi-hui.Comparative Study on Piglet Weaning Stress Syndrome and Diarrhea Type Irritable Bowel Syndrome with Liver Stagnation and Spleen Deficiency Syndrome[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(3): 44-.
[13]	LIAO Yu-mei, XUE Ya-dong, CHEN Sheng, et al. Research Progress of Anti-inflammatory Activity of PPARs Agonist in the Treatment of Depression[J]. ACTA NEUROPHARMACOLOGICA, 2021, 11(2): 32-38.
[14]	FAN Xukun, SUN Yi, SONG Shuangshuang, CONG Yifan, HOU Xueqin.Effects of Osthole on Cortical Neurotransmitters and the Anxietyand Depresion-Like Behaviors in the Oxytocin Receptor-Silencing Rats#br#[J]. ACTA NEUROPHARMACOLOGICA, 2021, 11(1): 11-17.
[15]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.